Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Solithromycin in Adolescents and Children With Community-Acquired Bacterial Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of and/or documented fever (rectal, ear, or oral temperature ≥38°C or axillary temperature ≥37.5°C) or hypothermia (rectal, ear, or oral temperature \<35°C or axillary temperature \<34.5°C)~* Chest radiograph infiltrates consistent with bacterial pneumonia (or pneumonia caused by atypical bacterial agents); if a subject is outpatient and starting on oral therapy, a radiograph is not required.~* Presence of at least 2 of the following signs or symptoms:~* Cough~* Difficulty breathing~* Production of purulent sputum~* Chest pain~* Grunting~* Hypotension~* Tachycardia, defined as follows:~  2 months to \<24 months: ≥160 beats/min 24 months to \<10 years: ≥140 beats/min~ * 10 years: ≥100 beats/min~* Tachypnea, defined as follows:~  2 months to \<12 months: ≥50 breaths/min 12 months to \<5 years: ≥40 breaths/min~ * 5 years: ≥20 breaths/min~* Physical exam consistent with pulmonary consolidation~* Presence of at least 1 of the following:~* Leukocytosis (≥12,000 white blood cells \[WBC\]/mm3)~* Leukopenia (\<5000 WBC/mm3)~* ≥10% immature neutrophils (bands) regardless of total peripheral WBC~* Elevated inflammatory markers (C-reactive protein or procalcitonin)~* Oxygen saturation \<97% on room air~* Organism consistent with a typical respiratory pathogen identified~Exclusion Criteria:~* Ventilator-associated or hospital-acquired pneumonia~* \>48 hours of systemic antibacterial therapy~* confirmed or suspected bacterial meningitis~* breast-feeding females~* positive pregnancy test

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Solithromycin (Type: EXPERIMENTAL): Solithromycin will be administered orally, as capsules or as a suspension, or intravenously. Patients may receive intravenous therapy initially and switch to an oral formulation. Dosage is weight based and age based.
- Standard of Care (Type: ACTIVE_COMPARATOR): Comparators will be selected according to subject age and are consistent with current recommendations for treatment of CABP in children. These include intravenous ceftriaxone, ampicillin, and amoxicillin and oral amoxicillin and amoxicillin-clavulanic acid. Azithromycin or erythromycin may be added as well.

Based on this trial design, predict the completion outcome and termination type (if applicable).